When a sprinter explodes out of the blocks, the first few seconds of effort are powered not by oxygen or glucose but by phosphocreatine, a molecule that regenerates ATP faster than any other metabolic pathway in the body. That much has been textbook physiology for decades. What has received far less public attention is that the same rapid-fire energy system operates in two other organs where milliseconds matter: the brain and the heart. As of June 2026, a growing body of primary human research confirms that the creatine kinase (CK) system functions as a critical ATP buffer in cardiac and neural tissue, not just in skeletal muscle. The implications stretch well beyond the weight room.
The core biochemistry, measured in living people
The creatine kinase reaction is simple in outline: the enzyme transfers a phosphate group from phosphocreatine (PCr) to ADP, regenerating ATP almost instantaneously at the enzymatic level. What makes recent work compelling is that scientists can now watch this reaction happen in real time inside living human organs using a technique called 31P magnetic resonance spectroscopy with saturation transfer (31P ST-MRS). This method quantifies the actual rate at which phosphocreatine converts to ATP in a specific tissue, providing hard biophysical data rather than indirect estimates.
In the heart, researchers have used 31P ST-MRS to directly measure ATP flux through creatine kinase in human myocardium. Their findings confirmed that the CK reaction is a quantitatively major ATP-regenerating pathway in cardiac muscle, and that CK-mediated energy turnover shifts measurably with workload and disease state. In failing hearts, CK flux drops, which helps explain why energy-starved cardiac tissue struggles to meet contractile demands even when oxygen delivery is adequate.
In the brain, a magnetization transfer study found that phosphocreatine turnover through creatine kinase increases in the visual cortex during visual stimulation, while steady-state concentrations of high-energy phosphates remain relatively stable. That stability is the key finding: the brain does not simply drain its energy reserves when neurons fire harder. Instead, the CK system accelerates its cycling rate, replenishing ATP fast enough to keep concentrations level even as demand spikes. The brain, in effect, has a built-in surge protector.
Why the system works so fast
Speed alone does not explain the CK system’s importance. Its architecture does. A detailed review published in Amino Acids describes how distinct creatine kinase isoforms are strategically positioned inside mitochondria and in the cytosol, creating what amounts to an energy shuttle. In the heart, mitochondrial CK generates phosphocreatine near the site of oxidative phosphorylation. That phosphocreatine then diffuses rapidly across the cell to cytosolic CK, which regenerates ATP right where it is consumed, at myosin ATPases during contraction, for example. This spatial relay solves a problem that simple diffusion of ATP molecules could not: delivering energy across cellular distances on a timescale that matches the demands of a beating heart.
Neurons face an analogous challenge. Synaptic transmission and ion channel activity create intense, localized ATP demands that fluctuate on a millisecond-to-second timescale. A review in Frontiers in Neuroscience consolidates evidence that the phosphocreatine system acts as both an energy reserve and a spatial shuttle in neurons and glial cells, buffering ATP during these transient demand spikes. Separate primary research has shown that expression of mitochondrial creatine kinase in brain regions including the cortex and hippocampus is regulated by neural activity itself, meaning the system scales its own capacity in proportion to how hard the brain is working.
What regulators have recognized
The European Food Safety Authority (EFSA) evaluated the evidence and concluded in EFSA Journal 2011;9(7):2303 that creatine increases physical performance in successive bursts of short-term, high-intensity exercise, authorizing that specific health claim for use with creatine monohydrate at a dose of 3 grams per day. The assessment focused on exercise performance rather than brain or cardiac function, but it validated the underlying bioenergetic principle: supplemental creatine expands the phosphocreatine pool, which accelerates ATP regeneration during repeated, intense energy demands.
No equivalent regulatory determination exists from the U.S. Food and Drug Administration, which classifies creatine as a dietary supplement and has not evaluated specific health claims for it. The International Society of Sports Nutrition (ISSN) position stand, updated in 2017, describes creatine monohydrate as the most effective ergogenic nutritional supplement available for increasing high-intensity exercise capacity and lean body mass, and notes that it has an acceptable safety profile in healthy populations at recommended doses.
Where the evidence runs thin
No published human trial has directly demonstrated that oral creatine supplementation increases measurable ATP flux in the brain during a defined cognitive task. The existing brain evidence confirms that the endogenous CK system ramps up during neuronal activation, but whether adding exogenous creatine meaningfully enhances that response in healthy adults has not been tested with real-time 31P MRS during cognitive load. A 2018 meta-analysis by Avgerinos and colleagues in Experimental Gerontology found that creatine supplementation may improve short-term memory and reasoning, particularly under conditions of stress or sleep deprivation, but the included studies relied on behavioral outcomes rather than direct imaging of brain energy metabolism.
Longitudinal data on how CK kinetics change in aging hearts or brains is also missing. The cardiac and brain imaging studies cited above are cross-sectional snapshots, not prospective tracking of individuals over years. Animal models have informed hypotheses about age-related decline in CK flux, but translating those findings to human aging trajectories requires studies that have not yet been completed.
Safety questions are comparatively well characterized for short-term use in healthy adults, largely from sports nutrition research. The ISSN position stand found no compelling evidence that creatine monohydrate causes kidney damage in healthy individuals. However, data in people with pre-existing kidney disease remain sparse, and rigorous long-term trials in older adults, patients with neurodegenerative conditions, or individuals with chronic heart failure have not been conducted. For these groups, the balance between potential energetic benefits and unknown risks has not been systematically mapped.
No major health authority has issued dosing guidelines for creatine use aimed specifically at brain or cardiac support. Claims about creatine as a brain or heart supplement therefore rest on mechanistic plausibility and early-stage evidence rather than the dose-response data that regulators typically require before endorsing clinical use.
Practical context: form, dose, and dietary sources
For readers wondering about practical details, creatine monohydrate is the most studied form and the one referenced in both the EFSA opinion and the ISSN position stand. The standard supplementation protocol involves either a loading phase of roughly 20 grams per day (split into four doses) for five to seven days followed by a maintenance dose of 3 to 5 grams per day, or simply taking 3 to 5 grams daily without loading, which saturates muscle creatine stores over approximately three to four weeks.
Dietary creatine comes primarily from red meat and fish. A pound of raw beef contains roughly 1 to 2 grams of creatine, meaning that typical omnivorous diets supply about 1 to 2 grams per day. Vegetarians and vegans, who get virtually no dietary creatine, tend to have lower baseline muscle creatine stores and may see larger relative increases from supplementation, a pattern that some researchers believe could extend to brain creatine levels as well, though direct evidence on this point remains limited.
What this means for people who are not athletes
The most defensible takeaway is that the creatine kinase system is a central, rapid-response energy buffer in both the heart and the brain, and that this system can be measured and perturbed in living humans. Oral creatine clearly supports repeated high-intensity muscular work, as recognized by EFSA and the ISSN. It almost certainly raises phosphocreatine availability in other tissues as well, given that creatine is taken up by cells throughout the body via a specific transporter.
Whether that translates into meaningful improvements in cognition, protection against neurological or cardiac disease, or tangible benefits in aging remains an open research question. Mechanistic plausibility is strong. The direct human imaging data are genuinely impressive. But the gap between observing faster CK flux in a stimulated visual cortex and proving that a daily scoop of creatine monohydrate protects against cognitive decline is wide, and no shortcut of inference can close it.
For clinicians and researchers, the priority is clear: combine precise imaging of CK flux with carefully designed supplementation trials and long-term outcome tracking. For consumers, the honest summary is that creatine’s role in the brain and heart is biologically important, experimentally accessible, and clinically intriguing, but still, in key respects, scientifically unfinished. That is not a reason to dismiss it. It is a reason to watch the science closely and resist the urge to outrun it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
